New multiomics horizons: metabolomics + proteomics

We’re excited to announce that Nightingale Health is extending its multiomics offering by adding Alamar’s NULISA CNS and Inflammation Panels. This new proteomics capability builds on our long-standing mission to make molecular data more accessible and interpretable, enabling researchers to gain a deeper understanding of health and disease from a single blood sample.

A new layer of biological insight: NULISA proteomics

Nightingale Health’s high-throughput metabolomics platform has profiled some of the world’s largest biobanks and clinical studies, providing detailed molecular fingerprints of metabolic health. The addition of ultra-sensitive proteomics provided by NULISA assay introduces a new layer of biological insight – bridging metabolic function with protein-level signals that drive pathophysiology in the brain, immune system, and beyond.

Alamar’s NULISA technology combines nucleic acid–linked immunoassay chemistry with digital counting to achieve attomolar sensitivity and an exceptionally broad dynamic range. This makes it possible to detect even tiny protein concentrations in blood—from signaling molecules and cytokines to brain-derived proteins traditionally thought to be measurable only in cerebrospinal fluid. The result is a proteomic view that complements and extends Nightingale Health’s established metabolomic profiles, creating a more complete molecular portrait of the health state of each sample donor.

New possibilities for brain health, neurodegeneration, autoimmune diseases, cancers, and aging

The NULISA CNS Panel focuses on proteins involved in brain health and neurodegeneration, including markers of neuronal integrity, synaptic function, glial activation, and pathological protein aggregation. Recent studies using this technology have highlighted its ability to accurately measure proteins such as brain-derived phosphorylated tau-217 and other CNS-related biomarkers that are emerging as prominent indicators of dementia risk and prognosis.

Nightingale Health will also offer the NULISA Inflammation Panel, focused on inflammatory biomarkers with strong relevance to autoimmune diseases, many cancers, and aging. The NULISA Inflammation Panel comprises 250 protein biomarkers with exquisitely sensitive measurement. Together, these panels make it possible to interrogate how systemic inflammation, metabolism, and brain biology intersect in health and disease.

Designed for research needs: Nightingale Health for Research is your Multiomics Hub

In addition to deeper biological insights, this combined offering provides practical simplicity. Samples are processed at Nightingale Health’s laboratory in a standardized workflow, ensuring consistency and reproducibility. The NULISA proteomic assays deliver data ready for integration with metabolomic biomarkers and clinical phenotype information. The combined biomarker panels open new avenues for understanding how molecular changes occur across disease trajectories and relate to the onset of clinical symptoms.

By bringing NULISA’s ultra-sensitive proteomics into our service portfolio, Nightingale Health aims to give researchers a unified platform to explore biology at multiple molecular scales. We believe this integration of metabolomics and proteomics represents the next logical step in multiomics research – bringing us closer to decoding the complex interplay between metabolism, inflammation, and brain health.

For more information on study design and access to the NULISA CNS and Inflammation Panels within Nightingale Health’s service framework, please contact us: research@nightingalehealth.com.